Tvardi Therapeutics Misses Q4 Net Loss Estimates by Over 25%
TVRD is trading near its 52-week low of $3.05 (0.0% above the low).
Summary
Tvardi Therapeutics reported a larger-than-expected net loss for the fourth quarter, missing analyst consensus estimates. The company posted a net loss of $7.30 million, significantly wider than the $5.67 million loss anticipated by analysts. This financial miss could put pressure on the stock, especially as it trades near its 52-week low. While the company stated its cash runway is expected to fund operations into Q4 2026, covering clinical readouts, the immediate earnings disappointment is a material concern for investors. Traders will be watching for further updates on clinical trial progress for TTI-101 and TTI-109, as well as future financial performance.
At the time of this announcement, TVRD was trading at $3.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.8M. The 52-week trading range was $3.05 to $43.65. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.